Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Exact Sciences, Alternative Biomedical Solutions, MedGenome, Exosome Diagnostics

NEW YORK (360Dx) – Investment bank William Blair said in a note to investors this week that Anthem Blue Cross of Indiana, Kentucky, Missouri, Ohio, and Wisconsin published a Network eUpdate that included an in-network laboratory update for Exact Sciences. This update does not affect the positive coverage decision from Anthem Blue Cross for Exact's colon cancer test Cologuard, but is the result of a request from Exact to move from an in-network, contracted lab to an out-of-network provider with Anthem, the bank noted. The switch became effective Jan. 1. The decision was based on Anthem beginning to include the use of prior authorization requirements for Cologuard, the note added.


Private investment firm Centre Lane Partners said this week that it recently completed the acquisition of Carrollton, Texas-based Alternative Biomedical Solutions, an ISO-certified supplier of mass spectrometry, toxicology, and chemistry measurement systems. ABS offers a line of analyzers, reagents, consumables, laboratory data management systems, and customized service agreements. Centre Lane Principal William James said in a statement that the investment firm believes ABS is "well-positioned to continue its growth in the toxicology testing market.”


Indian firm MedGenome said that its next-generation sequencing-based clinical lab in Bangalore has received accreditation from the College of American Pathologists. As a result, MedGenome is CAP-accredited for whole genome and exome sequencing, preimplantation genetic screening, preimplantation genetic diagnosis, cell-free DNA testing for liquid biopsy, and noninvasive prenatal testing, as well as high-resolution HLA typing.


Exosome Diagnostics said this week that its ExoDx Prostate IntelliScore (EPI) will now be supported by a national urology sales team. EPI is designed to reduce unnecessary initial prostate biopsies in men 50 years of age or older, with a PSA value between 2 and 10 ng/ml.  


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.